LQ-001

N/A

Report date: 2023/02/28 10:38:11

Base Information

Drug NameLQ-001
Drug Alias NameLQ-001LQ001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-Cluster of differentiation 47
TargetsCluster of differentiation 47
Therapy Area/IndicationsOvarian NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A